TFF2, a novel serum diagnostic biomarker for early pancreatic cancer.

ABSTRACT:

Background

Early detection and intervention are critical for improving the prognosis of pancreatic cancer (PC), but effective screening tests remain unavailable.

Methods

A retrospective analysis was conducted on 92 PC cases, 50 benign pancreatic disease cases, 92 periampullary adenocarcinoma cases, and 92 healthy controls from September 2020 to September 2024 at Handan Central Hospital. Serum levels of CA199 and CEA were measured, and their diagnostic performance was evaluated by the area under the receiver operating characteristic (ROC) curve (AUC). Additionally, publicly available cancer genome datasets were analyzed to identify specific serum biomarkers for early PC, and clinical serum samples were collected to validate their expression and diagnostic utility.

Results<

SUBMITTER: Wu X 

PROVIDER: S-EPMC12484238 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature